Search clinical trials for: Placebo to glargine

Total 60748 results

Cerecin

Completed

Tricaprilin in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Cerecin

Completed

Tricaprilin In Age-Associated Memory Impairment

Age-Associated Memory Impairment

United States
SIGA Technologies
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers (SIGA-246-002)

Healthy

United States
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes (AWARD-9)

Diabetes Mellitus, Type 2

United States, Czechia, Hungary, Italy, Puerto Rico, Spain, United Kingdom
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (GLITTER 1)

Diabetes Mellitus, Type 1

Spain, United States, Germany, Czechia, Hungary, Poland
Emory University

Completed

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients (CABG-D/C)

Poor Glycemic Control

United States
Sanofi

Completed

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Type 1 Diabetes Mellitus

Germany
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
GlaxoSmithKline

Recruiting

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Hepatitis B

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469

Healthy

Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

Healthy

Germany
Merck Sharp & Dohme LLC

Completed

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

Alzheimer Disease
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

Healthy
Novartis

Completed

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Essential Hypertension

Germany, Spain, United States
Novaremed Ltd.

Completed

Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients

Diabetic Peripheral Neuropathic Pain

Israel
Bionorica SE

Completed

Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Acute Rhinosinusitis

Germany
Sanofi

Completed

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (Soli-CGM)

Type 2 Diabetes Mellitus

United States
India Diabetes Research Foundation & Dr. A. Ramachandran...

Completed

A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients

Type2 Diabetes

India
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
University of Colorado, Denver

Completed

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

Type 1 Diabetes Mellitus | Diabetic Ketoacidosis

United States
Sanofi

Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (ARTEMIS-DM)

Type 2 Diabetes Mellitus

Argentina, Colombia, Egypt, Hong Kong, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Turkey
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (GLITTER 2)

Diabetes Mellitus, Type 2

United States
Sandra Sobel

Completed

Remission Through Early Monitored Insulin Therapy - Duration Month (REMIT-DM)

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

DOMME Dose Optimization Multicentric Mexican Evaluation (DOMME)

Diabetes Mellitus, Type 2

Mexico
Sumitomo Pharma Co., Ltd.

Completed

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Schizophrenia

China, Japan, Korea, Republic of, Malaysia, Philippines, Russian Federation, Taiwan, Ukraine
University Medical Center Goettingen

Completed

Observational Follow-up Study of REGATTA (REGATTA II)

Urinary Tract Infections

Germany
University Medical Center Goettingen

Completed

Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial (REGATTA)

Urinary Tract Infections

Germany
NeuroBo Pharmaceuticals Inc.

Recruiting

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Obesity

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Takeda

Terminated

Fasiglifam 25 mg BID vs 50 mg QD

Type 2 Diabetes Mellitus

United States, Poland, Ukraine, Taiwan, Bulgaria, Romania, Slovakia
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Healthy

Germany
Allergan

Completed

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United States, Czech Republic, Germany
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Recruiting

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2

United States, India, Spain, Poland, South Africa, Bulgaria, Germany, Japan, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Italy, Mexico, Russian Federation, United Kingdom, Spain, Malaysia, Croatia, Greece, Korea, Republic of, Japan, South Africa, Algeria, Thailand, Argentina, Brazil, Canada, Romania
Novo Nordisk A/S

Completed

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, Japan, Malaysia, Taiwan, Thailand, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Puerto Rico, Slovakia, Canada, South Africa, United Kingdom, Czech Republic

3

Subscribe